Curanex Pharmaceuticals Inc

For the period ended Jun 30, 2025. Filed Sep 9, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Sep 9, 2025

CURX$6.21+7.4%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Cash Flows

	For the Six Months Ended June 30,
2025 · 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period		$(197,929)	$(124,401)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Amortization of right-of-use assets		29,663	-
Interest expense		(4,447)	-
Changes in operating assets and liabilities:
Prepaid expenses		(5,110)	-
Lease liabilities		(29,048)	-
Accounts payable		(4,731)	-
Interest payable		4,447	-
Accrued expenses		(4,553)	(13,676)
Other current assets		(228,321)	(192,128)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES		(440,029)	(330,205)
CASH FLOWS FROM FINANCING ACTIVITIES:
Loan from shareholders		400,000	-
Issuance of common stock		-	630,000
Issuance of preferred stock		-	100
NET CASH PROVIDED BY FINANCING ACTIVITIES		400,000	630,100
Effect of Exchange Rate Changes on Cash
NET INCREASE (DECREASE) IN CASH		(40,029)	299,895
Cash at beginning of period		148,891	74,366
CASH AT END OF PERIOD		$108,862	$374,261
Supplemental schedule of cash flow information:
Non-cash investing & financing activities:
Issuance of common stock with a non-cash payment	$	-	$100,000
Recognition of right-of-use asset in exchange for lease liability		105,501	-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.